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Objectives: We hypothesized that the increased prevalence of noninfectious comorbidities 
(NICMs) observed among HIV-infected patients may result in increased direct costs of medical 
care compared to the general population. Our objective was to provide estimates of and describe 
factors contributing to direct costs for medical care among HIV-infected patients, focusing on 
NICM care expenditure.
Methods: A case-control study analyzing direct medical care costs in 2009. Antiretroviral 
therapy (ART)-experienced HIV-infected patients (cases) were compared to age, sex, and 
race-matched adults from the general population, included in the CINECA ARNO database 
(controls). NICMs evaluated included cardiovascular disease, hypertension, diabetes mellitus, 
bone fractures, and renal failure. Medical care cost information evaluated included pharmacy, 
outpatient, and inpatient hospital expenditures. Linear regression models were constructed to 
evaluate predictors of total care cost for the controls and cases.
Results: There were 2854 cases and 8562 controls. Mean age was 46 years and 37% were women. 
We analyzed data from 29,275 drug prescription records. Positive predictors of health care cost 
in the overall population: HIV infection (β = 2878; confidence interval (CI) = 2001–3755); 
polypathology (β = 8911; CI = 8356–9466); age (β = 62; CI = 45–79); and ART exposure 
(β = 18,773; CI = 17,873–19,672). Predictors of health care cost among cases: Center for Disease 
Control group C (β = 1548; CI = 330–2766); polypathology (β = 11,081; CI = 9447–12,716); 
age . 50 years (β = 1903; CI = 542–3264); protease inhibitor exposure (per month of use; 
β = 69; CI = 53–85); CD4 count , 200 cells/mm3 (β = 5438; CI = 3082–7795); and ART drug 
change (per change; β = 911; CI = 716–1106).
Conclusion: Total cost of medical care is higher in cases than controls. Lower medical costs 
associated with higher CD4 strata are offset by increases in the care costs needed for advancing 
age, particularly for NICMs.
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Background
HIV disease is the largest pandemic of the modern age and absorbs an enormous amount 
of health care resources. Estimates of the cost of treating HIV infection appeared soon 
after the availability of highly active antiretroviral therapy (ART) to prove cost efficacy 
of new drugs available in the late 1990s.1–3 These drugs were very costly but very 
convenient for health care systems due to the impact of ART in decreasing mortality 
and reducing hospital utilization.4–7
In the 1990s it became clear that CD4 cell count was not only a very sensitive 
surrogate marker of AIDS mortality, but also a major determinant of health care cost: 
the lower the CD4 the higher the direct cost of medical care.8,9
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This result was also confirmed in a study of medical care 
cost for patients who present late (CD4 , 200 cells/mm3) 
with HIV infection. These patients appeared to consume 
more than 200% higher care cost in the year following HIV 
diagnosis than patients who present with higher CD4.10
The clinical picture of HIV disease has changed rapidly 
in the last 10 years. Noninfectious comorbidities (NICMs) 
including cardiovascular disease (CVD), hypertension (Htn), 
bone fractures, renal failure, and diabetes mellitus (DM), 
became the most frequently observed causes of morbidity 
and mortality in HIV-infected patients.11–17 NICMs aggregate 
to give rise to complex polypathology pictures that typically 
occur in advanced age and describe geriatric syndromes.18–20 
We hypothesized that the increased prevalence of NICMs 
observed among HIV-infected patients may result in 
increased direct cost of medical care in respect to the general 
population.21,22 It is necessary to update total cost of medical 
care in HIV in order to better predict resource and allocation 
needs for the care of people living with HIV (PLWHA).
Our objective was to provide estimates and determinants 
of direct cost of medical care for HIV-infected patients, 
including direct cost of NICMs.
Methods
This is a case-control study analyzing all direct medical costs 
in the 2009 calendar year.
Cases  were  ART-exper ienced  HIV- in fec ted 
patients . 18 years of age who had access to the metabolic 
clinic of the University of Modena and Reggio Emilia, 
Modena, Italy.
This outpatient clinic is a multidisciplinary center for 
the management of NICMs in ART-experienced patients, as 
previously described.23 Patients attending this referral service 
are the patients attending the Modena HIV clinic as well as 
individuals referred from neighboring HIV centers.
Controls were matched according to age, sex, race, and 
geographical area and were selected from the CINECA 
ARNO observational database.24 The ARNO Observatory 
is an online, multicenter, observational database in which 
population-based data is collected and epidemiological 
methods are used to combine and aggregate huge volumes 
of health and health care-related data for each individual 
patient. These data include primary care provider-generated 
medication prescriptions, records from hospital admissions 
and discharges, diagnostic laboratory tests, and radiographic 
examinations. This information is linked to other sources 
of patient data (including vital statistics and patient 
demographics) in order to construct a tool that is used 
to provide comprehensive tracking of clinical diagnoses 
and health care use trends throughout Italy. The ARNO 
observatory has been active since 1986 and includes health 
care prescription data generated by 8300 general practitioners 
for a population of 11 million persons cared for at 32 health 
units in Italy. The database is updated monthly.
Direct health care cost analysis
Direct health care cost was retrospectively analyzed in the 
2009 calendar year using the following indicators:
1.	 Hospitalization cost: calculated by collecting International 
Classification of Diseases (ICD)-9 codes in cases and 
controls. All hospitalization with a primary or secondary 
ICD-9 comorbidity diagnosis code, including CVD, Htn, 
DM, bone fractures, and renal failure diagnosis, were 
selected.25
2.	 Outpatient HIV medical care cost. With the movement 
of HIV care into the outpatient setting, it was no longer 
possible to evaluate the cost of medical care using ICD-9 
codes, therefore we decided to attribute a mean patient 
care cost obtained by the most recent reference value 
able to better define HIV-related care cost in patients 
with ART. This estimate is adjusted for current CD4 
count strata and, in particular, it accounts for US$1,381/
year for patients with CD4 , 75 cells/mm3, US$1,241/
year for 76 , CD4 , 200 cells/mm3 and US$190/year 
for CD4 . 201 cells/mm3.26
3.	 NICM medication cost: calculated using pharmaceutical 
tracing by average wholesale prices obtained by 
the Agenzia Italiana del Farmaco (AIFA) national 
pharmaceutical handbook.27
4.	 ART medication cost: calculated using pharmaceutical 
tracing, by average hospital sale price.
Total cost is defined as the sum of mean of NICM costs plus 
mean of HIV hospitalization costs plus mean of drug costs.
For the purpose of this study, the following NICM 
conditions were eligible for the assessment of direct cost: 
CVD, Htn, DM, bone fractures, and renal failure. ICD-9 
hospital codes and drug tracing criteria were used to 
identify NICM diagnoses and direct medical cost in the 
study population. Polypathology (Pp) was defined as the 
simultaneous presence of two or more NICMs.28
The category of CVD included the following diagnoses: 
myocardial infarction, coronary artery disease, peripheral 
vascular disease, stroke, angina pectoris, coronary artery 
bypass grafting, and angioplasty.
In cases, the following HIV-specific variables were 
collected from patient charts:
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•	 Cumulative exposure to nonnucleoside reverse tran-
scriptase inhibitors (NNRTIs), nucleoside RTIs (NRTIs), 
and protease inhibitors (PIs)
•	 Number of previous ART drug switch before the current 
regimen
•	 Current CD4 , 200/mm3
•	 Age categories “young” and “old,” using 50 years as the 
cutoff age
•	 HIV viral load was categorized as undetectable if ,40 
copies/mL
•	 Previous AIDS diagnosis was defined according to the 
Centers for Disease Control and Prevention (CDC) group 
“C” category.29
Statistical analysis
Comparisons of variables considered in our study, performed 
between groups and among age strata, were analyzed using 
χ2-test for categorical variables and t-test or analysis of 
variance (ANOVA) for continuous variables. P-value , 0.05 
was considered significant. Post hoc analyses were performed 
using Bonferroni’s adjustment and significance level was 
considered for P , 0.008.
Considering the non-normal distribution of total costs, 
generalized linear models (GLMs) were constructed to 
evaluate independent factors associated with total cost in 
the whole population and in the subgroup of HIV-infected 
patients, using inverse Gaussian family distribution.
In the regression analysis in the HIV-positive cohort, age 
was stratified using the threshold of 50 years to evaluate the 
effect of aging on total cost.
The variables for regression analyses were chosen on the 
basis of their clinical relevance.
Statistical analyses were conducted using the Intercooled 
STATA software package, version 12.1 for Mac (StataCorp 
LP, College Station, TX, USA).
Results
There were 2854 cases and 8562 controls included in the 
analysis; 4244 (37%) were women; the mean age of the 
overall population was 46 (±8) years.
Among cases, the median duration of HIV infection 
was 196 months (range 36–248), median CD4 nadir was 
170 (interquartile range [IQR] 66–263.5), median current 
CD4 was 520 (IQR 374–702). Plasma HIV RNA levels were 
below the limit of quantification in 1825 cases (71.3%). 
The cumulative NRTI, NNRTI, and PI exposures were 
116 (IQR 72–155), 37 (IQR 16–70), and 55 (IQR 29–88) 
months, respectively. A CD4 nadir , 200 was documented in 
1525 (57.5%) cases. Twenty-nine thousand and two-hundred 
seventy-five (29,275) drug records were analyzed.
Figure 1 shows the comparative prevalence of NICMs 
and Pp observed in 2009 among HIV-infected versus (vs) 
uninfected patients, stratified by age. A significantly higher 
prevalence of renal failure, bone fractures, and DM was 
observed in HIV-infected patients compared to controls in all 
age strata. Across all age strata, Pp prevalence was significantly 
higher in cases compared to controls (all P-values , 0.001).
Pp prevalence in cases aged 41–50 years was 
nonstatistically different from the prevalence observed in 
controls aged 51–60 years (9.09% vs 6.61%; P = 0.010), 












Figure 1 Comparative risk of hypertension, diabetes, cardiovascular disease (CVD), fracture, and renal failure, by age strata, among cases and controls.
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resulting in an “anticipated” effect of Pp prevalence of almost 
10 years in cases compared to controls.
The anticipated effect of 10 years in Pp prevalence 
resulted in a parallel anticipated effect of 20–30 years in total 
direct cost: the mean total direct cost spent in cases aged less 
than 40 years was nonstatistically different from the total cost 
spent in controls aged more than 60 years (US$1,968.53 vs 
US$2,783.38; P = 0.615).
In order to give better insight to the major determinants 
of medical cost, Figure 2 compares the direct cost of HIV 
outpatient, and ART and NICM. Increased age was associated 
with increased direct cost of NICM both in cases and controls 
(P , 0.001).
In cases only, total direct cost was compared in young 
and old HIV-infected patients stratified for low and high CD4 
counts. The total annual cost of medical care for HIV-infected 
patients younger than 50 years and with CD4 , 200 cells/mm3 
was not significantly different to the total annual cost of 
medical care for HIV-infected patients older than 50 years 
and with CD4 . 200 cells/mm3 (US$16,614 vs US$14,061; 
P = 0.244). Total annual direct cost of HIV-infected patients 
older than 50 years and with CD4 , 200 cells/mm3 was the 
highest of the group comparisons (US$14,061) (Figure 3).
A linear regression model was built to identify independent 
predictors of total cost in the whole population (Table 1). 
Predictors of total cost were: HIV infection (β = 1.10; 
confidence interval (CI) = 1.09–1.11); Pp (β = 0.90; 
CI = 0.898–0.899); age (β = 0.016; CI = 0.016–0.016); 
ART exposure (β = 1.594; CI = 1.591–1.596); and male sex 
(β = 0.018; CI = 0.018–0.019).
A second linear regression model was built to identify 
independent predictors of total cost in HIV-infected patients 
only (Table 2).
Predictors of total cost in cases were: CDC group C 
(β = 0.069; CI = 0.069–0.070); Pp (β = 0.667; CI = 0.666–0.668); 
age . 50 years (β = 0.108; CI = 0.107–0.109); male sex 
(β = 0.017; CI = 0.016–0.018); PI exposure per month 
(β = 0.003; CI = 0.003–0.003); CD4 , 200 (β = 0.233; 
CI = 0.232–0.234); according to number of ART switch 
(β = 0.022; CI = 0.022–0.022).
Discussion
At least 3.0 million years of life have been saved in the 
United States as a direct result of care of patients with 
AIDS, highlighting the significant advances made in HIV 
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Figure 2 Total cost of medical care in cases and controls stratified by age decades.
Abbreviations: ART, antiretroviral therapy; NICM, noninfectious comorbidity.
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years age strata of HIV-infected patients (US$10,588.45) to 
those older than 60 years (US$21,280.72).
In order to make total direct cost estimates more generali-
zable, we stratified cost on age categories (young vs old) 
and traditional immunological markers of HIV disease 
(CD4 , 200 vs .200 cells/mm3).39 We confirmed that CD4 
count is a powerful indicator of the burden of care costs; 
in fact inpatient costs increase as patients become more 
immunosuppressed.21,40 Nevertheless, this indicator did 
not appear to change across age strata. On the contrary, the 






















Figure 3 Comparison between the cost of medical care for HIV-infected patients younger than 50 years with CD4 , 200 cells/mm3 and older than 50 years with 
CD4 . 200 cells/mm3.
Table 1 Multivariable regression analysis of independent factors 
associated with total cost in HIV-infected patients
β coefficient 95% CI P-value
Male sex 0.018 0.018–0.019 ,0.001
Age 0.016 0.016–0.016 ,0.001
Polypathology 0.90 0.898–0.899 ,0.001
HIV infection 1.10 1.09–1.11 ,0.001
ART assumption 1.594 1.591–1.596 ,0.001
Abbreviation: ART, antiretroviral therapy; CI, confidence interval.
Table 2 Multivariable regression analysis of independent factors 
associated with total cost in HIV-infected patients
β coefficient 95% CI P-value
Male sex 0.017 0.016–0.018 ,0.001
Age . 50 years 0.108 0.107–0.109 0.002
Current CD4 less than 
200 cells/mm3
0.233 0.232–0.234 ,0.001
CDC C category29 0.069 0.069–0.070 ,0.001
Polypathology 0.667 0.666–0.668 ,0.001
NRTI exposure, months −0.0004 −0.0004; −0.0004 ,0.001
NNRTI exposure, months 0.0006 0.0005–0.0006 ,0.001
PI exposure, months 0.003 0.003–0.003 ,0.001
Number of therapy 
switches
0.022 0.022–0.022 ,0.001
Abbreviations: CDC, Centers for Disease Control and Prevention; NNRTI, 
nonnucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcrip-
tase inhibitors; PI, protease inhibitor; CI, confidence interval.
that achieved for patients with many other chronic diseases 
in the US, but its immediate consequence is an expected 
increase in cost of medical care due to longer survival of 
PLWHA on ART.30–36 This survival increase implies not only 
longer cumulative exposure of ART per single patient but 
also an increase in cost secondary to age-related diseases, as 
previously described in the general population.37 Moreover, 
these clinical conditions, aggregating in Pp, appear to 
occur at a younger age in HIV-infected patients, causing a 
“premature aging process”38 in these patients, as previously 
demonstrated in the same cohort but with a 7-year period of 
observation.23,38
The present study aimed to provide estimates and 
determinants of direct cost of HIV care in the ART era.
With regards to estimates, we were able to demonstrate that 
the total direct cost increases two-fold moving from the ,40 
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driving determinant of the age-related effect was the direct 
cost of NICMs.
Chen et al, in a study analyzing distribution of health 
care expenditures for HIV-infected patients in the early 
ART era, but did not take into account the costs derived 
from toxicities or comorbidities.40 They stated that this 
exclusion was unlikely to have a major impact on the 
analysis of care cost. The current scenario in the advanced 
ART era is much changed. It is now clear that NICMs 
are not simply the result of direct ART toxicity but rather 
a complex interplay of host virus and drug-risk factors 
resulting in Pp and translating to a premature aging process 
affecting HIV-infected patients.20,41–43 It is quite striking 
that, in the logistic regression analyses, Pp accounted for 
a cost expenditure three times higher than that of HIV 
infection per se.
Summary
The key points of this study are:
1.	 The total cost of medical care is higher in HIV-infected 
patients than in the general population in any age strata. 
This issue is quite obvious, given that ART medication 
cost accounts for the majority of the total care cost.3,21,44 
This cost did not appear to vary across age groups. 
Besides that, we were also able to demonstrate that 
NICM care costs contributed significantly to this higher 
cost burden of HIV-infected patients in the context of a 
premature aging process producing an anticipation effect 
of more than 20 years in total direct cost. This study was 
able to demonstrate that the premature aging process 
affecting HIV-infected patients translates to a premature 
cost expenditure in this population. We believe it is 
necessary to continue to monitor in prospective studies 
the impact of the HIV-specific accelerated aging process 
on total care cost. Pp accounts for a cost expenditure three 
times higher than that of HIV infection per se (US$8,911 
vs US$2,878).
2.	 The reduction of total care cost observed in the increasing 
CD4 strata was compensated by the increase of the total 
care cost observed across age strata. 
3.	 Focusing on independent predictors of total cost in HIV-
infected patients, we confirmed that low CD4 cell count 
and CDC group C play a relevant role with regard to health 
care expenditure. This should reinforce what has already 
been suggested by Krentz and Gill, that early initiation 
of ART may result in a cost-saving intervention.26 
Previous ART exposure accounted for a low proportion of 
increase cost that resulted as significant only for PIs. On 
the contrary the number of therapy switches represented a 
good indicator of increased cost of ART, presumably due 
to mega-ART combination and use of newer and more 
costly drugs.
We therefore believe that, in an epidemiological situ-
ation in which the majority of PLWHA will be older than 
50 years by the year 2015, health care providers may 
expect an increase in total care cost for the HIV-infected 
population.21,47,48
How will the health care system 
be able to face this changing scenario?
Where possible, the cost of HIV treatment and care needs 
to be reduced without reducing the quality of services, and, 
once again, we need to stress that prevention programs need 
to become more effective.44
While high-income countries are struggling to meet these 
increasing costs, middle- and lower-income countries with 
larger epidemics are likely to find it even more difficult to 
meet these increasing demands, given that they have fewer 
resources.48
Limitations
This study has several limitations, unavoidable in the cross-
sectional nature of its design. We provided drug cost values 
in dollars for the purpose of an international interpretation 
of the results. Nevertheless, we need to underline that any 
pharmacoeconomic analysis must be strictly contextualized 
in the setting in which it was generated.
As previously shown, the metabolic clinic setting, 
despite being a referral service, still continues to be 
representative of HIV outpatients living in northern Italy, 
given that the prevalence of NICMs was not different 
between the metabolic clinic cohort and the Modena HIV 
cohort.38
We firmly believe that a better knowledge of health care 
determinants will allow for a better allocation of health care 
resources.
Conclusion
What we have observed in this study is that the total cost of 
medical care is higher in HIV-infected patients in comparison 
with HIV-negative controls. Lower medical costs associated 
with higher CD4 strata are offset by increases in the care costs 
needed for advancing age, particularly for NICMs.
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